Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Olaparib and Pembrolizumab in HRD-Positive Ovarian Cancer
NCT04417192Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Center Hospital East. Started Dec 2020; status: completed.
02
Drugs
olaparibpembrolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04417192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417192.